SCHEMBL6019148

SCHEMBL6019148

CCOC(=O)c1cc2cc(N)ccc2n1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MAPT P10636 4/20 0.50
GAA P10253 1/20 0.50
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
SIRT2 Q8IXJ6 2/20 0.47
SIRT1 Q96EB6 2/20 0.47
TSHR P16473 1/20 0.46
POLB P06746 1/20 0.46
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NOD2 Q9HC29 2/20 0.44
NOD1 Q9Y239 2/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
RECQL P46063 1/20 0.44
HPGD P15428 1/20 0.43
MAT2A P31153 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8296756 0.85 ALDH1A1 (0.63) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL22760557 0.84 MAPT (0.51) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL6019391 0.81 NOD2 (0.55) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL6173410 0.81 MEN1 (0.44) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL4421828 0.81 NOD2 (0.65) KDM4EMEN1KMT2ASMN1; SMN2NOD2
SCHEMBL1173839 0.80 MAPT (0.52) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL17323111 0.80 LMNA (0.47) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL22760540 0.80 ALDH1A1 (0.47) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL22760420 0.80 MAPT (0.47) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL17647214 0.79 MAPT (0.51) ALDH1A1MAPTGAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183753-A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases BAYER HEALTHCARE AG (DE) 2006-08-17 US disclosed
US-7045544-B2 Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2006-05-16 US disclosed
EP-1578418-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES Bayer HealthCare AG (DE) 2005-09-28 EP disclosed
US-20050038101-A1 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2005-02-17 US disclosed
WO-2004056768-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES BAYER HEALTHCARE AG (DE) 2004-07-08 WO disclosed
WO-2004056768-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES BAYER HEALTHCARE AG (DE) 2004-07-08 WO disclosed
WO-2003028719-A1 SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183753-A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases DCK, UROD, QDPR ALDH1A1 592/4885MAPT 2350/4885GAA 1975/4885
US-20050038101-A1 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases ECE1, ECE2, EDNRA ALDH1A1 199/4885MAPT 3259/4885GAA 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.